(Alliance News) - AstraZeneca PLC on Friday reported positive phase-three trial results for its chronic obstructive pulmonary disease treatment tozorakimab. The Cambridge, England-based pharmaceutical ...

* Shares among biggest gainers on FTSE 100 (Adds quote from interview with company executive in fourth paragraph, updates shares in third paragraph) March 27 (Reuters) - AstraZeneca's experimental ...

The iconic four-block takeover returns April 24 with dishes from more than 50 restaurants, more than 200 global sips, next-level entertainment, and Southern Glazer’s Wine & Spirits as exclusive ...

Italian researchers reporting in the journal Cancers found a 32% increase in the odds for cancer in the first year after a ...

Persistent morning stiffness and joint pain could signal rheumatoid arthritis, an autoimmune condition. A doctor explains ...

Savara Inc (NASDAQ:SVRA) shows rising activity as Nasdaq today trends highlight biopharmaceutical developments.

Dr James Fox explores the recent movements in the AstraZeneca share price and evaluates whether it's still a good long-term investment opportunity. The post What’s going on with the AstraZeneca share ...

Bengaluru: AstraZeneca said that a combination treatment with its cancer drug Imfinzi showed significant improvement in how ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society ...

Incyclix Bio, LLC, a cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...

UBS and Citi both maintain 'buy' ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich ...

March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, sending its shares up as much as 3.8% on Friday on ...